Former Chimerix CEO Andriole to lead Artios
Plus: Whiting named CMO of Vividion and updates from X4 and Gubra
Artios Pharma Ltd. hired Michael Andriole as CEO, succeeding founding CEO Niall Martin at the DNA damage response company. Andriole joins the trans-Atlantic biotech after serving as president and CEO of Chimerix Inc., which Jazz Pharmaceuticals plc (NASDAQ:JAZZ) acquired this year for $935 million. Artios’ alnodesertib (formerly ART0380) is an ATR inhibitor in Phase Ib/II trials for multiple cancers. The company has raised at least $268 million since its founding in 2016.
Sam Whiting joined Vividion Therapeutics Inc. as CMO. He was CMO and head of R&D at Tempest Therapeutics Inc. (NASDAQ:TPST), where he oversaw the development of small molecules for cancer. Vividion is a subsidiary of Bayer AG (Xetra:BAYN) that develops therapies against difficult-to-drug targets in oncology and immunology...